Overcoming Bottlenecks in Biopharmaceutical Development
Keynote SeriesPharmaceutical Technology and BioPharm International are sponsoring a Keynote Series discussion on bioprocessing challenges on the INTERPHEX 2016 Exhibit Hall Innovation Stage. Admission is free to any attendee with an exhibit hall pass.
Tuesday, April 26, 10:15 am to 11:45 am
Overcoming Bottlenecks in Biopharmaceutical Development
In a panel discussion, industry experts will discuss how technology advances are addressing challenges in biopharmaceutical development including quality control of raw materials, implementation of single-use technologies, process monitoring, and downstream purification.
Panelists:
Marian L. McKee, PhD, Director, US Development Services, MilliporeSigma
Mike Goodwin, Director of R&D, SUT, Thermo Fisher Scientific
Alex Perieteanu, PhD, Director, Biopharmaceutical Services - Life Sciences, SGS Mississauga
Elizabeth Goodrich, Director of Applications Engineering, MilliporeSigma
To register: http://www.interphex.com/pharmtech
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
